.png)
Winning the Atopic Dermatitis (AD) launch: What leading brands get right in the first 18 months
We don’t just power insights. We power outcomes.
Infrastructure built for performance
We back pharma teams with scalable systems that drive launch success, scale omnichannel engagement, and streamline execution - from pre-launch to market leadership
Engagement designed to activate
We enable pharma teams to run behavior-led journeys for patients and HCPs - with smart nudges, targeted content, and the right channels to drive adherence and impact
Evidence shaped to influence
We equip pharma teams with insights that shape strategy and build HCP trust - tracking brand health, identifying key segments, and strengthening market position
“We founded Temedica to close the gap between clinical promise and real-world performance. We believe real progress starts with understanding behaviour, activating evidence, and connecting the dots - across patients, HCPs, and pharma - to deliver outcomes that really matter.”
Built with the industry, not in silos.
We’re backed by a seasoned Advisory Board of leaders from across the industry
Our Management
-
Gloria Seiber
Founder & Chief Executive Officer
-
Benjamin Friedrich
Founder & Chief Medical Officer
-
Alexandru Dina-Gargala
VP Product & Data
-
Marietherese Burghold
VP Business Development
Our Board of Experts and Advisors
Dr. Diane Seimetz
Is a leading expert in drug development and regulatory affairs with over 20 years of experience in the biopharmaceutical industry—from serving as Executive Vice President at Fresenius to co-founding Biopharma Excellence and guiding novel therapies toward early patient access. As an advisor to Temedica, she brings sharp strategic acumen in regulatory pathways, clinical development, and biotech innovation to support the company’s mission in personalized, data-driven patient care.
Dr. iur. Rainer Hess
Served as the impartial Chairman of Germany’s Federal Joint Committee (G-BA) from 2004 to 2012 and previously led the National Association of Statutory Health Insurance Physicians; he is a renowned legal expert in medical and social-health law. As an advisor to Temedica, he brings deep expertise in healthcare regulation, remuneration systems, and the legal frameworks underpinning Germany’s healthcare governance.
Dr. med. Markus Leyck Dieken
Former CEO of Gematik, is a specialist in internal and emergency medicine who brings over two decades of leadership in the biotech industry—including roles at Novo Nordisk, Novartis, and Teva—to the digital healthcare arena.
As an advisor to Temedica, he contributes deep expertise in strategic and regulatory matters, particularly in digital health transformation, market access, and personalized medicine built on real‑world evidence.
Dr. Stefan Oschmann
Is a distinguished pharmaceutical executive, best known for leading Merck KGaA as CEO and Chairman (2016–2021), where he orchestrated a transformation into a global science-and-technology powerhouse and championed digital innovation in healthcare. As an advisor to Temedica, he lends deep expertise in strategic leadership, global pharma ecosystems, and innovation-driven business transformation.
Prof. Dr. Dr. Sebastian Schneeweiss
Professor of Medicine and Epidemiology at Harvard Medical School and Chief of Pharmacoepidemiology at Brigham and Women’s Hospital, is an internationally acclaimed expert in real-world evidence, comparative effectiveness, and rapid-cycle analytics of healthcare data. As an advisor to Temedica, he brings cutting‑edge knowledge in transforming complex longitudinal healthcare databases into actionable, regulatory‑grade insights to drive precision and safety in patient care.
Prof. Dr. Norbert Klusen
Former Chairman of the Board of Techniker Krankenkasse, is a leading expert in health policy, insurance systems, and healthcare innovation. As an advisor to Temedica, he brings decades of strategic experience in shaping patient-centered, data-driven healthcare solutions.
Rudi Lamprecht
A seasoned IT industry executive with extensive leadership experience at Hewlett-Packard and Siemens, continues to serve on Temedica’s Expert Advisory Board, lending strategic insights from the technology and digital transformation sectors. His expertise in IT systems, operational scale-up, and enterprise software innovation enhances Temedica's capabilities in data-driven healthcare solutions.
Why pharma partners love working with us
Thanks to Temedica’s health insights, we gain a profound and precise understanding of care realities and patient journeys of individual patient cohorts. This knowledge enables us to plan our initiatives with greater precision and to focus even more on the individual needs of patients.
.png?width=227&height=224&name=the%20circle%20(1).png)
Maira Trauzettel
Head of Marketing & Customer Excellence
.png?width=766&height=758&name=Lilly%20(1).png)
Temedica's Permea Disease Navigator and Services confirmed our initial assumptions and revealed new insights into co-medications, co-morbidities, and regional diagnostics, enhancing our region-specific strategy development.
Joerg Schaub
Associate VP Neuroscience
.png?width=766&height=758&name=Group%207809%20(4).png)
I am impressed with Temedica's analytical capabilities. By incorporating its many insights and perspectives into our decision-making processes, we have achieved a significant transformation. We gain comprehensive insights into trends, behaviors, and specific needs related to women's health, enabling us to make informed business decisions.
Claudine Petit
Digital Go-to-Market Lead, Central & Northern Europe
The expansive data landscape of the Temedica ecosystem is a treasure trove for scientists to produce actionable insights for clinical practice.
-2.png?width=227&height=224&name=the%20circle%20(6)-2.png)
Prof. Dr. Dr. Sebastian Schneeweiss
Professor of Medicine and Epidemiology
Based on my experience in Real-World Evidence research, I like Temedica's innovative approach to facilitate a prompt, comprehensive, and precise understanding of patient journeys, disease burden, and health outcomes, particularly in the field of multiple sclerosis.
Natalie Joschko
Principal Medical Leader Neuroimmunology
As a collaboration partner with Temedica, we are excited about their novel insights. These have the potential to take today's approach to medicine to a new level - for example, by combining real-world insights from digital tools with various other intelligent sources of information to sustainably improve patient care.
-3.png?width=227&height=224&name=the%20circle%20(6)-3.png)
Dr. Michael Staudigl
Cell Therapy Lead Germany
The Brisa Patient Companion has opened new doors in how we interact with and understand MS patients. Its ability to provide real-time, actionable insights serves as a bridge, connecting patient experiences with our care strategies, leading to more personalized and effective treatments.
.png?width=227&height=224&name=the%20circle%20(2).png)
Viktoria Renz
Senior Patient Partnership Manager Neuroimmunology
The Permea Disease Navigator shed light on crucial insights we didn’t even realize we were missing. It’s changing the trajectory of our efforts in product development and marketing.
Lothar Guske
General Manager
Temedica's extensive ecosystem, rich with real-world insights, proves indispensable in my work on 'digital twins.' This allows for personalized diagnoses and a deeper understanding of disease phenotypes. Together with Temedica, we're transitioning to concise, data-driven narratives, thereby promoting patient understanding and transparency.
.png?width=227&height=224&name=the%20circle%20(6).png)
Prof. Dr. med. Tjalf Ziemssen
Director Center of Clinical Neuroscience
-2.png?width=766&height=758&name=Roche%20(1)-2.png)
I value Temedica’s ability to deliver valuable insights into market segments where we previously had limited quantitative data.
-1.png?width=227&height=224&name=the%20circle%20(2)-1.png)
Ralf Zimmermann
Head of Business Unit Ophthalmology
You have questions?
We have answers!
Looking to learn more about Temedica?
In this section, you’ll find answers to the questions we hear most often, covering our vision, our solutions, and how we support patients, partners, and the healthcare ecosystem.
FAQs
What is Temedica?
Temedica is a leading health insights and engagement company that transforms real-world data into actionable intelligence. We help pharmaceutical companies, healthcare providers, and stakeholders make better decisions through AI-powered analytics, patient engagement solutions, and omnichannel communication strategies.
What is Temedica’s mission?
Our mission is to make healthcare more personalized, data-driven, and outcome-focused. We connect and analyze patient, HCP, and market data to deliver insights that improve brand performance, enhance patient journeys, and accelerate medical innovation.
How does Temedica differentiate from other health data companies?
We stand out through our unique combination of proprietary real-world evidence sources, advanced AI analytics, and configurable engagement solutions. Unlike standard providers, we tailor every insight and engagement journey to the specific brand, role, and market needs of our clients.
Who does Temedica work with?
We collaborate with global pharmaceutical companies, biotech innovators, healthcare providers, and industry partners to improve decision-making, launch strategies, patient adherence, and long-term brand success.
FAQs
What solutions does Temedica offer?
Our portfolio includes:
- Permea Insight Hub for real-world data analytics.
- Omnichannel Engagement Suite for HCP and patient engagement.
- Strategic Services to translate insights into measurable commercial impact.
Where is Temedica based?
Temedica is headquartered in Munich, Germany, with a growing international footprint to support global healthcare markets.
How does Temedica ensure data privacy and compliance?
We operate under strict GDPR and industry compliance standards, ensuring that all real-world data we process is pseudonymized or anonymized, secure, and ethically managed.
Get in touch today!
